|
gptkbp:instanceOf
|
gptkb:antiparasitic_drug
|
|
gptkbp:approvedBy
|
1981
|
|
gptkbp:ATCCode
|
P02CF01
|
|
gptkbp:brand
|
gptkb:Sklice
gptkb:Soolantra
gptkb:Stromectol
|
|
gptkbp:CASNumber
|
70288-86-7
|
|
gptkbp:chemicalFormula
|
C48H74O14
|
|
gptkbp:contraindication
|
children under 15 kg
lactation (caution)
pregnancy (caution)
|
|
gptkbp:discoveredBy
|
gptkb:Satoshi_Ōmura
gptkb:William_C._Campbell
1975
|
|
gptkbp:drugClass
|
gptkb:anthelmintic
antiparasitic
|
|
gptkbp:eliminationHalfLife
|
12–36 hours
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:KEGGID
|
D04538
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to glutamate-gated chloride channels
causes paralysis and death of parasites
|
|
gptkbp:MeSH_ID
|
D007089
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
875.1 g/mol
|
|
gptkbp:NobelPrizeYear
|
gptkb:2015_Nobel_Prize_in_Physiology_or_Medicine
|
|
gptkbp:notRecommendedFor
|
COVID-19 treatment (no proven efficacy)
|
|
gptkbp:origin
|
derived from avermectin
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Streptomyces_avermitilis
|
|
gptkbp:PubChem_CID
|
6321424
CHEMBL1239
DB00602
|
|
gptkbp:routeOfAdministration
|
oral
topical
|
|
gptkbp:sideEffect
|
nausea
diarrhea
dizziness
itching
rash
swelling
|
|
gptkbp:UNII
|
91Y2202OUW
|
|
gptkbp:usedFor
|
treatment of head lice
treatment of lymphatic filariasis
treatment of onchocerciasis
treatment of parasitic infections
treatment of river blindness
treatment of scabies
treatment of strongyloidiasis
|
|
gptkbp:bfsParent
|
gptkb:Satoshi_Ōmura
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ivermectin
|